Skip to main content

Georgina Arrambide García

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Georgina Arrambide García

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

Diagnostic and prognostic biomarkers in pediatric multiple sclerosis and related demyelinating disorders

IP: Mar Tintore Subirana
Collaborators: Cristina Auger Acosta, Georgina Arrambide García, Alex Rovira Cañellas, Mireia Del Toro Riera, Angela Vidal Jordana, Luciana Midaglia Fernandez
Funding agency: Fundació La Marató de TV3
Funding: 100000
Reference: 20141831
Duration: 22/05/2015 - 22/11/2018

Esclerosis múltiple: redefiniendo la historia natural

IP: -
Collaborators: Jordi Rio Izquierdo, Georgina Arrambide García, Elena Huerga Núñez, Alex Rovira Cañellas, Angela Vidal Jordana
Funding agency: Instituto de Salud Carlos III
Funding: 105875
Reference: PI14/01439
Duration: 01/01/2015 - 31/12/2017

Las proteínas morfogenéticas óseas como posibles biomarcadores en la esclerosis múltiple: expresión en lesiones y líquido cefalorraquídeo de pacientes con esclerosis múltiple

IP: Carmen Espejo Ruiz
Collaborators: Herena Eixarch Ahufinger, Georgina Arrambide García, Mar Tintore Subirana, Elena Antima Martinez Saez
Funding agency: Fundación Merck Salud
Funding: 25000
Reference: SERONO-2013-04
Duration: 01/05/2014 - 01/11/2016

Aportaciones de la resonancia magnética de alto campo al estudio diagnóstico de pacientes con primeros brotes sugestivos de esclerosis múltiple

IP: Mar Tintore Subirana
Collaborators: Rosalia Horno Ocaña, Carmen Tur Gomez, Cristina Auger Acosta, Georgina Arrambide García, Elena Huerga Núñez, Joaquin Castillo Justribo, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 80465
Reference: PI12/01313
Duration: 01/01/2013 - 30/06/2016

Related news

An international study led by researchers from Vall d’Hebron shows that simple tests that patients can perform themselves help detect changes in disability that may occur even in the absence of disease relapses.

A Vall d’Hebron study, carried out at Cemcat, shows that the risk of inflammatory activity increases after discontinuing treatment, but is considerably reduced in people over 60 years of age.

The project will analyse the functional activation of the NLRP3 inflammasome to advance the early identification of patients at risk of insufficient response to S1P receptor-modulating therapies.

Related professionals

Edurne Ruiz Marti

Edurne Ruiz Marti

Research assistant
Infectious Diseases
Read more
Ariadna Campos Martorell

Ariadna Campos Martorell

Senior researcher
Growth and Development
Read more
Javier Hoyo Pérez

Javier Hoyo Pérez

Administration and Management
Neurodegenerative Diseases
Read more
José Manuel Vidal Taboada

José Manuel Vidal Taboada

Main researcher
Peripheral Nervous System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.